Literature DB >> 23512981

Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia.

Derek S Steele, Hyun-Seok Hwang, Björn C Knollmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23512981      PMCID： PMC3657388          DOI： 10.1093/cvr/cvt059

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  15 in total

1.  Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Hyun Seok Hwang; Can Hasdemir; Derek Laver; Divya Mehra; Kutsal Turhan; Michela Faggioni; Huiyong Yin; Björn C Knollmann
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-01-26

2.  Ryanodine receptor inhibition potentiates the activity of Na channel blockers against spontaneous calcium elevations and delayed afterdepolarizations in Langendorff-perfused rabbit ventricles.

Authors:  Young Soo Lee; Mitsunori Maruyama; Po Cheng Chang; Hyung Wook Park; Kyoung-Suk Rhee; Yu-Cheng Hsieh; Chia-Hsiang Hsueh; Changyu Shen; Shien-Fong Lin; Hyun Seok Hwang; Huiyong Yin; Björn C Knollmann; Peng-Sheng Chen
Journal:  Heart Rhythm       Date:  2012-03-01       Impact factor: 6.343

3.  Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Christian van der Werf; Prince J Kannankeril; Frederic Sacher; Andrew D Krahn; Sami Viskin; Antoine Leenhardt; Wataru Shimizu; Naokata Sumitomo; Frank A Fish; Zahurul A Bhuiyan; Albert R Willems; Maurits J van der Veen; Hiroshi Watanabe; Julien Laborderie; Michel Haïssaguerre; Björn C Knollmann; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

4.  Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release.

Authors:  Qiang Zhou; Jianmin Xiao; Dawei Jiang; Ruiwu Wang; Kannan Vembaiyan; Aixia Wang; Chris D Smith; Cuihong Xie; Wenqian Chen; Jingqun Zhang; Xixi Tian; Peter P Jones; Xiaowei Zhong; Ang Guo; Haiyan Chen; Lin Zhang; Weizhong Zhu; Dongmei Yang; Xiaodong Li; Ju Chen; Anne M Gillis; Henry J Duff; Heping Cheng; Arthur M Feldman; Long-Sheng Song; Michael Fill; Thomas G Back; S R Wayne Chen
Journal:  Nat Med       Date:  2011-07-10       Impact factor: 53.440

5.  Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.

Authors:  Nian Liu; Marco Denegri; Yanfei Ruan; José Everardo Avelino-Cruz; Andrea Perissi; Sara Negri; Carlo Napolitano; William A Coetzee; Penelope A Boyden; Silvia G Priori
Journal:  Circ Res       Date:  2011-06-16       Impact factor: 17.367

6.  Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.

Authors:  Eleonora Savio Galimberti; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2011-07-12       Impact factor: 5.000

7.  Mechanism of antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Hiroshi Watanabe; Derek S Steele; Björn C Knollmann
Journal:  Circ Res       Date:  2011-09-02       Impact factor: 17.367

8.  Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Hiroshi Watanabe; Christian van der Werf; Ferran Roses-Noguer; Arnon Adler; Naokata Sumitomo; Christian Veltmann; Raphael Rosso; Zahurul A Bhuiyan; Hennie Bikker; Prince J Kannankeril; Minoru Horie; Tohru Minamino; Sami Viskin; Björn C Knollmann; Jan Till; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2012-12-31       Impact factor: 6.343

Review 9.  Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia.

Authors:  Nian Liu; Carlo Napolitano; Luigi A Venetucci; Silvia G Priori
Journal:  Trends Cardiovasc Med       Date:  2012-08-04       Impact factor: 6.677

10.  Flecainide reduces Ca(2+) spark and wave frequency via inhibition of the sarcolemmal sodium current.

Authors:  Markus B Sikkel; Thomas P Collins; Christina Rowlands; Mit Shah; Peter O'Gara; Alan J Williams; Sian E Harding; Alexander R Lyon; Kenneth T MacLeod
Journal:  Cardiovasc Res       Date:  2013-01-19       Impact factor: 10.787
View more
  7 in total

1.  Reply from Pei-Chi Yang, Jonathan D. Moreno, Mao-Tsuen Jeng, Xander H. T. Wehrens, Sergei Noskov and Colleen E. Clancy.

Authors:  Pei-Chi Yang; Jonathan D Moreno; Mao-Tsuen Jeng; Xander H T Wehrens; Sergei Noskov; Colleen E Clancy
Journal:  J Physiol       Date:  2016-11-01       Impact factor: 5.182

Review 2.  Investigational antiarrhythmic agents: promising drugs in early clinical development.

Authors:  Jordi Heijman; Shokoufeh Ghezelbash; Dobromir Dobrev
Journal:  Expert Opin Investig Drugs       Date:  2017-07-20       Impact factor: 6.206

Review 3.  Calcium Signaling and Cardiac Arrhythmias.

Authors:  Andrew P Landstrom; Dobromir Dobrev; Xander H T Wehrens
Journal:  Circ Res       Date:  2017-06-09       Impact factor: 17.367

4.  Multiple modes of ryanodine receptor 2 inhibition by flecainide.

Authors:  D Mehra; M S Imtiaz; D F van Helden; B C Knollmann; D R Laver
Journal:  Mol Pharmacol       Date:  2014-10-01       Impact factor: 4.436

5.  Targeting pathological leak of ryanodine receptors: preclinical progress and the potential impact on treatments for cardiac arrhythmias and heart failure.

Authors:  Patrick Connell; Tarah A Word; Xander H T Wehrens
Journal:  Expert Opin Ther Targets       Date:  2020-01-03       Impact factor: 6.902

6.  Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor.

Authors:  Mark L Bannister; Anita Alvarez-Laviada; N Lowri Thomas; Sammy A Mason; Sharon Coleman; Christo L du Plessis; Abbygail T Moran; David Neill-Hall; Hasnah Osman; Mark C Bagley; Kenneth T MacLeod; Christopher H George; Alan J Williams
Journal:  Br J Pharmacol       Date:  2016-06-29       Impact factor: 8.739

7.  Molecular Changes in the Cardiac RyR2 With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

Authors:  Angela F Dulhunty
Journal:  Front Physiol       Date:  2022-02-10       Impact factor: 4.566
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.